Skip to Content

Bismuth Subcitrate Potassium / Metronidazole / Tetracycline Dosage

Applies to the following strength(s): 140 mg-125 mg-125 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Helicobacter pylori Infection

Bismuth subcitrate potassium 420 mg-metronidazole 375 mg-tetracycline 375 mg orally 4 times a day (after meals and at bedtime)
-Duration of therapy: 10 days

Comment: Omeprazole should be given orally 2 times a day during treatment (after morning and evening meals).

Use: Eradication of Helicobacter pylori infection in patients with active or a history (e.g., within 5 years) of duodenal ulcer infection and/or disease

Usual Pediatric Dose for Helicobacter pylori Infection

8 years and older: Bismuth subcitrate potassium 420 mg-metronidazole 375 mg-tetracycline 375 mg orally 4 times a day (after meals and at bedtime)
-Duration of therapy: 10 days

Comment: Omeprazole should be given orally 2 times a day during treatment (after morning and evening meals).

Use: Eradication of Helicobacter pylori infection in patients with active or a history (e.g., within 5 years) of duodenal ulcer infection and/or disease

Renal Dose Adjustments

Mild to moderate renal impairment: Data not available
Severe renal impairment: Contraindicated

Liver Dose Adjustments

Mild to moderate hepatic dysfunction (Child-Pugh A and B): Use with caution; monitoring is recommended.
Severe hepatic dysfunction (Child-Pugh C): Not recommended.

Precautions

US BOXED WARNINGS: POTENTIAL FOR CARCINOGENICITY
-Metronidazole has been shown to be carcinogenic in mice and rats.
-It is unknown whether metronidazole is associated with carcinogenicity in humans.

Safety and efficacy have not been established in patients younger than 8 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug should be given with a full glass of water (e.g., 8 ounces), especially the bedtime dose.
-If a dose is missed, patients should continue the normal dosing schedule; patients should not take double doses.

Monitoring:
-Dermatologic: Erythema/photosensitivity, signs/symptoms of cutaneous reactions
-Hematologic: Initial and post-treatment total and differential leukocyte counts, especially in patients with evidence/history of blood dyscrasias
-Ocular: Ophthalmologic evaluation in patients who develop visual disturbances

Patient advice:
-Tell patients that it is important to complete the full regimen.
-Instruct patients to seek medical attention if signs/symptoms of hypersensitivity, abnormal neurological effects, photosensitivity, or other cutaneous reactions occur.
-Patients should be told to avoid unprotected exposure to sunlight/UV light during treatment.
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Hide